T-DXd was first approved by the FDA for this indication in 2019, and it has since also been approved for HER2-low metastatic BC, HER2-positive advanced GC, and HER2-mutant metastatic non-small-cell lung cancer. This evidence concerns the gene ERBB2 and gastric cancer.